CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 451,036 enrolled / 451,036 target
Drug / intervention
GLP-1 receptor agonist +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07465926
NCT07465926N/ACompletedMonitor (3957.5/mo)Completion was 5mo ago
CompareCT.gov

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

Chung Shan Medical University·observational·Posted Mar 12, 2026·Updated Jun 22, 2026

In Brief

An observational study evaluating GLP-1 receptor agonist and SGLT2 inhibitor for Cardiovascular-kidney-metabolic Syndrome and 4 related conditions. Completed, enrolled 451,036 participants.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3 who initiate a GLP-1 receptor agonist or an SGLT2 inhibitor. The study compares patients who, within 90 days of starting background therapy, add the alternate agent, add a DPP-4 inhibitor or sulfonylurea, or do not receive early add-on therapy. The primary outcome is all-cause mortality over 36 months, with secondary cardiorenal outcomes also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease, Type 2 Diabetes, Obesity & Overweight
Countries--
CollaboratorsNational Science and Technology Council, Taiwan

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 12, 2026
Enrollment StartJan 1, 2017
Primary CompletionJan 31, 2026
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 4 months ago

Arms & Interventions

GLP-1 RA Base Therapyother

Adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3 who initiated a GLP-1 receptor agonist as base therapy after a 6-month washout from GLP-1 RA, SGLT2i, DPP-4i, and sulfonylureas. Within this cohort, participants were classified by the first add-on treatment within 90 days into three mutually exclusive strategies: SGLT2i add-on, DPP-4i or sulfonylurea add-on, or no early add-on.

Drug: GLP-1 receptor agonistDrug: SGLT2 inhibitor
SGLT2i Base Therapyother

Adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3 who initiated an SGLT2 inhibitor as base therapy after a 6-month washout from GLP-1 RA, SGLT2i, DPP-4i, and sulfonylureas. Within this cohort, participants were classified by the first add-on treatment within 90 days into three mutually exclusive strategies: GLP-1 RA add-on, DPP-4i or sulfonylurea add-on, or no early add-on.

Drug: GLP-1 receptor agonistDrug: SGLT2 inhibitor

Interventions

GLP-1 receptor agonistdrug

Use of a glucagon-like peptide-1 receptor agonist as background therapy or add-on therapy in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.

SGLT2 inhibitordrug

Use of a sodium-glucose cotransporter-2 inhibitor as background therapy or add-on therapy in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.